Physician profile
Paul Kaywin
NPI 1598752842
$4,674.72
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.17 · 2021: $112 · 2022: $1,500 · 2023: $152 · 2024: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,320 · Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,320.00 |
| Food and Beverage | $648.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,320.00 | 2024 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Merck Sharp & Dohme LLC | $111.64 | 2023-2024 | Keytruda |
| Amgen INC. | $99.95 | 2021 | |
| Array Biopharma INC | $97.61 | 2023-2024 | Xalkori, Lorbrena, Braftovi |
| Rigel Pharmaceuticals, INC. | $94.17 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $91.30 | 2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $82.15 | 2024 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $70.96 | 2023-2024 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $52.82 | 2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $29.70 | 2023 | |
| Janssen Biotech, INC. | $26.00 | 2023 | Erleada, Rybrevant |
| Janssen Scientific Affairs, LLC | $24.55 | 2024 | Rybrevant |
| Jazz Pharmaceuticals INC. | $24.36 | 2024 | |
| Novocure INC. | $19.50 | 2024 | Optune Lua (Novottf-200t) |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.09 | 2024 | Retevmo |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kaywin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.